关节腔内注射玻璃酸钠与安慰剂对照治疗早中期膝骨关节炎WOMAC评分的Meta分析

doi:10.3969/j.issn.1009-976X.2022.03.007

摘要/Abstract

摘要： 目的通过荟萃分析探讨关节腔内注射玻璃酸钠（HA）对比安慰剂（Placebo）治疗早中期膝骨性关节炎（KOA）的临床疗效。方法依据PICOS原则,检索并收集自建库至2020年9月15日,公开发表于Web of Science、Pubmed、Scopus、中国知网、万方、读秀学术、超星期刊和维普中文数据库关于关节腔内注射HA或Placebo治疗早中期KOA的双盲随机对照试验（RCT）临床文献,严格按照纳入和排除标准提取资料并用RoS2评价文献质量,采用Review Manager 5.3软件对数据进行荟萃分析。结果经过初检、泛读和精读以及数据提取后共纳入10个双盲RCT临床研究,包括2388名KOA患者,其中HA组1243名;Placebo组1145名。治疗后6个月,HA组WOMAC疼痛、僵硬或功能评分与基线的差值均明显低于Placebo组,分别为（MD=0.89,95%CI：0.44~1.34,P<0.001;MD=2.83,95%CI：1.42~4.25,P<0.001;MD=0.33,95%CI：0.07~0.59,P=0.01）,且异质性极低;治疗后6月,HA组WOMAC疼痛或功能评分均明显低于Placebo组,分别为（MD=-0.7,95%CI：-1.23~0.17,P=0.01;MD=-1.92,95%CI：-3.63~0.21,P=0.03）,但两组僵硬评分无明显差异（MD=-0.3,95%CI：-0.68~0.08,P=0.12）;治疗后6月,HA组疼痛VAS评分明显低于Placebo组（MD=-3.82,95%CI：-6.36~1.28,P=0.003）;应急止痛药物的使用无明显差异。结论关节腔内注射HA治疗早中期KOA患者疗效显著,治疗后半年较Placebo组可明显减轻膝痛,并改善患侧膝关节功能,而远期疗效需要进一步高质量的双盲RCT临床试验验证。

关键词: 膝骨关节炎, 玻璃酸钠, WOMAC评分, 双盲随机对照试验, Meta分析

Abstract: Objective To investigate the clinical efficacy of intra-articular injection of sodium hyaluronate （HA） versus placebo （Placebo） in the treatment of early and mid-stage knee osteoarthritis （KOA） was determined by the meta-analysis. Methods According to the PICOS principles, from the beginning of database construction until September 15, 2020 to search and collect the double-blind randomized controlled trial （RCT） clinical research literatures of intra-articular injection of HA or Placebo for early and mid-term KOA published in Web of Science, Pubmed, Scopus, CNKI, Wanfang, Duxiu Academic, Superstar Journals and VIP Chinese Database. The data were extracted in strict accordance with the inclusion and exclusion criteria, and the quality of the literatures were evaluated by RoS2. The data were meta-analyzed by the Review Manager 5.3 software. Results A total of 10 double-blind RCT clinical studies were included after initial examination, extensive reading, intensive reading, and data extraction, including 2388 KOA patients were enrolled, which including 1243 in the HA group and 1145 in the Placebo group. At 6 months after treatments, the WOMAC pain, stiffness, or functional scores in the HA group and the differences of these from the baselines were significantly lower than that in the Placebo group, MD=0.89,95%CI：0.44~1.34, P=0.0001; MD=2.83, 95%CI：1.42~4.25,P<0.001; MD=0.33,95%CI：0.07~0.59, P=0.01） respectively, and the heterogeneities are extremely low; at 6 months after treatments, the WOMAC pain or function scores in the HA group were significantly lower than that in the Placebo group, they were （MD=-0.7,95%CI：-1.23~-0.17,P=0.01; MD=-1.92,95%CI：-3.63~-0.21, P=0.03）, but there was no significant difference in stiffness score between the two groups （MD=-0.3,95%CI：-0.68~0.08, P=0.12）. The VAS score at 6 months in HA group were significantly lower than that of the Placebo group （MD=-3.82, 95%CI：-6.36~-1.28, P=0.003）; there was no significant difference in the uses of emergency analgesics. Conclusion Intra-articular injection of HA is effective in treating early and mid-term KOA patients. Compared with Placebo group, it can significantly reduce knee pain and improve knee joint function after half a year of treatments. The long-term effect requires further high-quality double-blind RCT clinical trials to verify.

Key words: knee osteoarthritis, sodium hyaluronate, WOMAC scores, double-blind randomized controlled trial, meta-analysis

中图分类号:

R684.3

吴子龙, 熊含颖, 袁权华. 关节腔内注射玻璃酸钠与安慰剂对照治疗早中期膝骨关节炎WOMAC评分的Meta分析[J]. 岭南现代临床外科, 2022, 22(03): 250-259.

WU Zi-long, XIONG Han-ying, YUAN Quan-hua. WOMAC scores of intra-articular injection of sodium hyaluronate and placebo in the treatment of early and mid-stage knee osteoarthritis： a meta-analysis[J]. Lingnan Modern Clinics In Surgery, 2022, 22(03): 250-259.

参考文献

[1] Miller RE, Scanzello CR, Malfait AM.An emerging role for Toll-like Receptors at the neuroimmune interface in osteoarthritis[J]. Semi Immunopathol,2019,41(5): 583-594.
[2] Hunter DJ, Bierma-Zeinstra S.Osteoarthritis[J]. Lancet,2019,393(10182):1745-1759.
[3] Kolasinski SL, Neogi T, Hochberg MC,et al.2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee[J]. Arthritis Rheumatol, 2020, 72(2):220-233.
[4] Ferreira de ACA, Genov IR, Pereira SRN, et al. Viscossuplementation for the treatment of osteoarthritis of the knee: A protocol for an umbrella review of systematic reviews with meta-analyses of randomized controlled trials[J]. Medicine (Baltimore), 2020, 99(37):e21813.
[5] 袁涛,席刚,韩鹏飞,等.关节腔内注射PRP与HA治疗膝关节骨性关节炎的荟萃分析[J].中国矫形外科杂志,2019,27(3):235-242.
[6] Higgins JP,Green S.Cochrane handbook for systematic reviews of interventions[M]. Hoboken: John Wiley & Sons, 2011.
[7] Liberati A, Altman DG, Tetzlaff J, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies thatevaluate health care interventions: explanation and elaboration[J]. Ann Int Med, 2009, 151(4):W65-94.
[8] Collins NJ, Misra D, Felson DT, et al. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS),Tegner Activity Score (TAS) [J]. Arthritis Care Res (Hoboken), 2011, Suppl 11(11): S208-228.
[9] Bellamy N.WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire[J]. J Rheumatol, 2002, 29(12):2473-2476.
[10] Higgins JPT,Savović J, Page MJ, et al. Chapter 8: Assessing risk of bias in a randomized trial [M/OL]. //Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updaeptemted Sber2020). Cochrane, 2020. http://www.training.cochrane.org/handbook.
[11] 陈泽华,叶翔凌,陈伟健,等.系统回顾和量化倒走治疗膝骨关节炎的Meta分析[J].中国组织工程研究,2020,24(26):4251-4256.
[12] Altman RD, Rosen JE, Bloch DA, et al.A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial)[J]. Semin Arthritis Rheum,2009,39(1): 1-9.
[13] Arden NK, Akermark C, Andersson M, et al.A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis[J]. Curr Med Res Opin,2014,30(2): 279-286.
[14] Baltzer AW, Moser C, Jansen SA, Krauspe R.Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis[J]. Osteoarthritis Cartilage, 2009, 17(2):152-160.
[15] Chevalier X, Jerosch J, Goupille P, et al.Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial[J]. Ann Rheum Dis,2010,69(1): 113-119.
[16] DeCaria JE, Montero-Odasso M, Wolfe D, et al. The effect of intra-articular hyaluronic acid treatment on gait velocity in older knee osteoarthritis patients:A randomised, controlled study[J].Arch Gerontol Geriatr,2012,55(2):310-315.
[17] Hangody L, Szody R, Lukasik P, et al.Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial[J]. Cartilage,2018,9(3): 276-283.
[18] Henrotin Y, Berenbaum F, Chevalier X, et al.Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE(R) CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial[J]. BMC Musculoskelet Disord,2017,18(1): 222.
[19] Petterson SC, Plancher KD.Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial[J]. Knee Surg Sports Traumatol Arthrosc,2019,27(6): 1992-2002.
[20] Huang TL, Chang CC, Lee CH, et al.Intra-articular injections of sodium hyaluronate (Hyalgan®) in osteoarthritis of the knee.a randomized, controlled, double-blind, multicenter trial in the asian population[J]. Bmc Musculoskeletal Disorders,2011,12: 221.
[21] Wullems JA, Bos E, et al.No difference between intra-articular injection of hyaluronic acid and placebo for mild to moderate knee osteoarthritis: a randomized, controlled, double-blind trial[J]. J Arthroplasty,2015,30(5): 754-757.
[22] Vincent TL.Mechanoflammation in osteoarthritis pathogenesis[J]. Semin Arthritis Rheum, 2019, 49(3S):S36-S38.
[23] Altman RD,Manjoo A,Fierlinger A, et al.The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review[J]. BMC Musculoskelet Disord, 2015,16:321.
[24] 刘爱峰,裴开源,王平,等.玻璃酸钠注射液与生理盐水对照对于膝骨性关节炎临床疗效的Meta分析[J].中国矫形外科杂志,2016,24(17):1581-1586.
[25] Ackerman I.Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)[J]. Aust J Physiother, 2009, 55(3):213.
[26] Copsey B, Thompson JY, Vadher K,et al.Problems persist in reporting of methods and results for the WOMAC measure in hip and knee osteoarthritis trials[J]. Qual Life Res,2019,28(2):335-343.